Bioaffinity technologies reports fourth quarter and full year 2022 financial results

San antonio--(business wire)--bioaffinity technologies, inc. (nasdaq: biaf; biafw), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported financial results for the three and 12 months ended december 31, 2022.
BIAF Ratings Summary
Quant
BIAF Quant Ranking
Sector
Industry
Quant Rating
Quant Score